Global Blood-Based Biomarkers Market Size, Trend & Opportunity Analysis Report, by Type (Genetic Biomarkers), Application (Cancer), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), End Use (Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others), and Forecast, 2025-2035
Global Blood-Based Biomarkers Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Blood-Based Biomarkers Market was valued at USD 7.85 billion in 2024 and is anticipated to reach USD 17.39 billion by 2035, expanding at a CAGR of 7.5% during the forecast period 2024–2035. Blood-related biomarkers have transformed the means for early detection of diseases, therapeutic monitoring, and the advancement of personalised medicine, a step-change in the way in which healthcare providers practice. These markers could transform the whole realm of cancer diagnostics, being minimally invasive blood markers that are able to detect changes on the molecular level as early as before the appearance of signs and symptoms. Their future integration into the framework of clinical decision-making will strengthen decision-making, improve patient outcomes, and lessen the burden of delayed diagnosis. With the moving trend toward precision medicine, blood-related biomarkers have assumed the role of principal players in the drug development arena, creating an ever-increasing demand, especially through oncology and other allied health sectors.
With this growing burden of cancer incidence abroad, the doctors are under pressure to work with diagnostic methods that are accurate, non-invasive, and yet can be applied to a large population. Thus, blood-based biomarkers supply exactly this balance, making them truly indispensable in the context of modern oncology. Advanced technologies have cut across NGS and PCR, facilitating rapid developments toward high-throughput analysis with improved detection sensitivity. Concomitant to that, however, the pharmaceutical industry has been exploiting these biomarkers within clinical trials for patient stratification, therapeutic monitoring, and relapse prediction to accelerate drug approval and market access.
On the supply side, diagnostic developers and biotechnology innovators are making significant investments to increase existing biomarker panels, develop automated platforms, and collaborate with academic institutions to validate their findings. These activities not only reduce clinical uncertainties but also fit squarely into regulatory pathways that are rapidly developing towards the acceptance of companion diagnostics. Invasive tissue biopsy methods are now being increasingly challenged by advanced paradigms toward liquid biopsy. Synergistically, research innovations, clinical adoption, and strategic partnerships have dramatically transformed the landscape of blood-based biomarkers, leading to an extensive growth section in the next ten years.
Recent Developments in the Industry
- In March 2024, Roche Diagnostics entered a partnership with Pfizer for the co-development of blood-based biomarker assays for oncology drug trials. This collaboration is geared towards generating companion diagnostics for the adoption of targeted therapy in the management of solid tumours.
- In November 2023, Illumina Inc. expanded its TruSight Oncology portfolio to include liquid biopsy capabilities for improved blood-based biomarker detection. This innovation has positioned the company to capitalise on the rapidly growing non-invasive diagnostics for early cancer screening.
- During July 2024, Guardant Health's Shield™ blood test for colorectal cancer screening was granted U.S. FDA approval. This regulatory clearance is an important landmark for the acceptance of liquid biopsy and speaks to the increasing validation of blood-based biomarkers in cancer diagnostics.
- In April 2024, Thermo Fisher Scientific announced a USD 400 million investment into its R&D facilities for biomarker research in the U.S. and Europe. This funding aims to accelerate the development of biomarker panels deployable in precision oncology and chronic disease management.
- In January 2025, Siemens Healthineers expanded its diagnostics manufacturing operations in India, focusing on the Asia Pacific market. The initiative aims to bolster access to affordable biomarker technologies for emerging economies with high cancer burdens.
- In October 2023, QIAGEN launched the QIAseq Multimodal Assay, enabling simultaneous detection of genetic biomarkers from a single blood sample. This innovation enhances workflow efficiency and broadens the diagnostic information that can be presented to clinical clinicians.
Market Dynamics
Rising cancer prevalence is driving robust demand for non-invasive diagnostic tools.
Cancer incidence continues to rise globally, leaving healthcare systems no choice but to embrace technologies for early detection that help avert lengthy treatment delays and enhance patient survival. Blood-based biomarkers have relatively less invasive means with maximum predictive accuracy, therefore becoming highly indispensable for oncologists on a fast track. By providing real-time information on tumour biology, these, in turn, decrease the burden on invasive biopsies, promoting patient compliance and resulting in lower costs for the healthcare system. The sudden surge in demand has further catalysed investments for biomarker research and acceptance in hospitals and diagnostic laboratories.
Technological advancements are accelerating biomarker discovery and clinical deployment.
The conjunction of next-generation sequencing, polymerase chain reaction, and bioinformatics is modifying the scenario of blood-based biomarker testing. Advanced sequencing platforms enable the detection of subtle genetic mutations, while PCR-based methods provide rapid and scalable diagnosis. Together with AI-driven analytics, these capabilities produce insights with clinical significance that underlie decisions for precision therapies. As these instruments become better established, a considerable expansion of the market is expected from their integration into standard diagnostic regimes.
Regulatory complexity and standardisation challenges are slowing market adoption.
Yet blood-based biomarkers do remain challenged by regulatory compliance and a lack of standardised validation protocols. Regulatory authorities, including the FDA and EMA, demand rigorous testing for clinical utility, which lengthens the timeline for approval and increases the cost of development. Furthermore, the absence of harmonised standards across geographies adds complications to the market adoption. These barriers highlight the need for collaborative efforts between regulators, industry, and academia to create streamlined validation frameworks that ensure biomarker safe use and reliability.
Opportunities emerging from liquid biopsy adoption and personalised medicine trends
The global trend towards personalised healthcare is a fertile ground for blood-based biomarkers. Liquid biopsy platforms, based on biomarker detection, are
likely to replace or complement conventional tissue biopsies, especially in oncology. Their ability to continuously monitor disease progression, treatment responses, and resistance mechanisms opens up new avenues for pharmaceutical R&D and clinical practice. This ongoing trend provides great opportunities for diagnostic developers to develop multipurpose assays for both research and clinical needs.
Market trends shaped by collaborations and cross-industry synergies
The biomarker ecosystem is more and more defined by collaborations between diagnostic developers, pharmaceutical companies, and academic research institutes. Such alliances accelerate validation processes, expand application scope, and enhance global market penetration. At the same time, M&A activities allow for portfolio diversification and access to advanced technology. These trends in cooperation are likely to shape the future competitive landscape of the blood-based biomarkers market, promoting rapid innovation and scaling.
Attractive Opportunities in the Market
• Liquid Biopsy Expansion – Rising adoption of blood-based tests provides non-invasive alternatives to traditional biopsies.
• Oncology Dominance – Cancer-focused biomarker development remains the largest growth avenue for diagnostic companies globally.
• Companion Diagnostics Growth – Pharma-diagnostics collaborations accelerate the adoption of biomarker-driven personalised treatments.
• Asia-Pacific Potential – Rapid healthcare expansion and cancer prevalence in emerging economies drive biomarker demand.
• AI Integration – Advanced analytics improve biomarker interpretation and precision in clinical decision-making.
• Regulatory Milestones – FDA and EMA approvals for blood-based assays accelerate adoption across oncology practices.
• NGS Advancements – Next-generation sequencing enables broader, more accurate biomarker detection from single samples.
• Cost-Effective Testing – Streamlined workflows and automation reduce per-test cost, enhancing affordability and accessibility.
• Academic-Industry Partnerships – Joint validation studies accelerate the translation of research biomarkers into clinical use.
• Chronic Disease Detection – Beyond cancer, applications in cardiovascular and neurodegenerative diseases unlock further opportunities.
Report Segmentation
By Type: Genetic Biomarkers
By Application: Cancer
By Technology: Next-Generation Sequencing, Polymerase Chain Reaction
By End Use: Hospitals & Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Roche Diagnostics, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Illumina Inc., QIAGEN N.V., Siemens Healthineers AG, Becton Dickinson and Company, Guardant Health Inc., Agilent Technologies Inc., and Foundation Medicine Inc.
Report Aspects
• Base Year: 2024
• Historic Years: 2022, 2023, 2024
• Forecast Period: 2024-2035
• Report Pages: 293
Dominating Segments
Genetic biomarkers have gained prominence due to their unparalleled ability to provide molecular insights into cancer progression, treatment resistance, and patient prognosis.
Since genetic alterations often precede visible symptoms, these biomarkers allow for timely intervention and greater therapeutic efficacy. Therefore, although genetic biomarker adoption is gaining momentum worldwide, it is becoming a top agenda item within health systems, especially in oncology, where they represent the backbone of companion diagnostics. As NGS technologies evolve, diagnostic accuracy will become superior with multiplexing and small blood volumes. Given the growth of personalised medicine, genetic biomarkers will remain at the leading edge of diagnostic innovation, fostering their acceptance in hospitals, diagnostic laboratories, and research institutes globally. Cancer applications spearhead biomarker adoption, fuelled by escalating prevalence and unmet clinical needs.
Blood-based biomarkers have application areas, with cancer taking the lead, thereby holding the largest market share.
This scenario is projected to sharply increase by 2035, needing considerable demand for reliable and minimally invasive diagnostic tools. Cancer biomarkers not only assist in early diagnosis but also help longitudinally track tumour dynamics, thereby giving oncologists the chance to monitor treatment response and alter therapeutic approaches as the treatment progresses. Currently, blood-based biomarkers are gaining importance for their support in clinical trials, where pharmaceutical companies are now more dependent on patient stratification based on biomarkers to ascertain drug efficacy. The advancements in liquid biopsy platforms will ensure that from now on, this segment will remain the leader in capturing the market.
NGS leads the technology battlefield, enhancing the sensitivity of biomarkers and multi-analyte capabilities.
Among the newer technologies for analysis of biomarkers, NGS is considered to be the leader, as it has unmatched sensitivity for several analytes. These NGS-based test sessions are extremely important in cancer diagnostics, where the detection of very rare mutations or minimal residual disease with very high resolution is required. Its ease of scaling and adaptability allow the NGS to be an ideal technology for clinical diagnostics and translational research. Besides, the incorporation of cloud-based bioinformatics has made the entire process very user-friendly and has resulted in the fast dissemination of NGS from advanced research centres to mainstream health care establishments. NGS will continue to hold the leading position, aided by lot cost reductions along with increased sequencing throughput.
Hospitals and clinics are the largest end-use segment making use of biomarkers in the delivery of patient-centred care.
Hospitals and clinics currently account for the largest market share when it comes to biomarkers since they represent the primary patient checkpoint for diagnostics and treatment. Clinicians are using blood-based biomarkers more and more to find therapeutic windows quickly, especially in practice pathways related to cancer. Such practices avoid being totally invasive while providing the healthcare team with prompt and required tools for that particular decision-making process. More integration of assays for biomarkers with the internal computer systems for hospital laboratories will boost efficiency and accuracy in diagnosis. With growing decentralisation and personalised care in cancer, hospitals and clinics will forever capture the end-use of biomarkers, which are propelled by increasing healthcare expenditure and diagnosis infrastructure going on worldwide.
Key Takeaways
• Cancer Application Leads – Biomarkers remain indispensable in oncology diagnostics and precision medicine.
• Genetic Biomarker Dominance – Genetic insights drive earlier interventions and personalised therapies.
• NGS Outpaces PCR – Next-generation sequencing drives high-sensitivity, multi-biomarker testing globally.
• Hospitals Retain Lead – Clinical adoption strengthens as hospitals remain primary diagnostic endpoints.
• Personalised Medicine Rise – Precision-based therapies push biomarker adoption into mainstream healthcare.
• Liquid Biopsy Momentum – Non-invasive blood-based platforms replace invasive tissue biopsies.
• Regulatory Approvals Surge – FDA and EMA endorsements accelerate global adoption of biomarker platforms.
• Asia-Pacific Growth – Expanding healthcare access and cancer incidence boost regional biomarker markets.
• Collaborations Accelerate – Pharma-diagnostics partnerships fast-track companion diagnostic development.
• Beyond Oncology Expansion – Biomarker applications in chronic disease diagnostics widen long-term prospects.
Regional Insights
North America continues to dominate the market in terms of better healthcare infrastructure and strong regulatory support.
North America remains the epicentre of blood-based biomarker adoption through the excellent healthcare system with its high oncology burden and investment in R&D. In this case, rapid regulatory pathways through the FDA, particularly these days, have improved investments in the U.S. by speeding up the approvals of blood tests. This has created intensified collaborative research efforts with academic institutions, biotech companies, and developers to validate biomarkers and their entry into clinical practice. Collaboration is further supported by the prevalence of strategic alliances formed by large pharmaceutical companies and diagnostic firms, promoting innovation and solidifying North America as the clear leader in developing markets of this nature.
Europe will be ahead in terms of regulatory-driven innovation and early adoption of liquid biopsy platforms.
Europe has thus achieved a leadership position in adopting biomarkers, spurred by comprehensive regulatory frameworks like the EU In Vitro Diagnostic Regulation (IVDR). Countries such as Germany, France, and the UK invest heavily in biomarker validation studies, particularly for oncology, to strengthen the clinical utility aspect. In addition, the commitment of Europe to precision medicine initiatives, coupled with government-funded healthcare systems, enables the establishment of fertile ground for adoption. Collaborative networks between universities and industry leaders have led to accelerated biomarker pipeline development, which makes Europe a strong contender in the world biomarker race.
Asia-Pacific emerges as the fastest-growing market due to industrialisation, coupled with increasing incidences of cancer.
The Asia-Pacific region is expected to grow at the highest CAGR among blood-based biomarker markets, fueled by a rapid pace of industrialisation and urbanisation, as well as growing incidences of cancer. Nations like China, India, and South Korea are engaged in building rapid growth in their diagnostic infrastructures along with increased government spending on healthcare innovation. Local biotech firms are forming partnerships with global diagnostics players to offer cost-effective biomarker solutions. Non-invasive diagnostics are becoming part of the Asia-Pacific and are expected to significantly influence the future in terms of biomarker adoption, aided by a growing patient population demanding such tests.
LAMEA has demonstrated sustainable growth with increasing investments in the healthcare sector and an increasing awareness of the burden of cancer.
LAMEA (Latin America, the Middle East, and Africa) has been slowly but surely catching up with biomarker adoption, even as it still grapples with problems such as inadequate infrastructure and lack of regulatory clarity. Brazil and the UAE have established themselves as regional hubs for advanced diagnostics by attracting multinationals that establish joint ventures and other partnerships to enhance availability. Increasing public awareness of cancer and investments in diagnostic laboratories have led to gradual improvements in adoption rates. Though not as fast as North America or Asia-Pacific, the region holds near-term future potential as healthcare modernisation accelerates.
Key Benefits for Stakeholders
• The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
• The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
• Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
• A detailed examination of market segmentation helps identify existing and emerging opportunities.
• Key countries within each region are analysed based on their revenue contributions to the overall market.
• The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
• The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion
Frequently Asked Question(FAQ) :
Oncology (cancer) applications spearhead the market and hold the largest share. This dominance is fueled by the rising global prevalence of cancer and the critical need for minimally invasive tools that can monitor tumor dynamics and treatment responses in real-time.
NGS is the leading technology in the market due to its high sensitivity and multi-analyte capabilities. It allows for the detection of rare genetic mutations and minimal residual disease from small blood volumes, making it superior to traditional methods for complex cancer diagnostics.
The shift is driven by the non-invasive nature of blood-based tests, which improve patient compliance and reduce healthcare costs. Liquid biopsies provide a more comprehensive view of tumor biology and allow for continuous monitoring of disease progression and resistance mechanisms without the risks associated with invasive surgery.
The Asia-Pacific region is anticipated to be the fastest-growing market. Growth is driven by rapid industrialization, increasing cancer incidence in nations like China and India, expanding diagnostic infrastructure, and rising government spending on healthcare innovation.
The market faces hurdles such as regulatory complexity and a lack of standardized validation protocols across different geographies. High development costs and the rigorous testing required by authorities like the FDA and EMA can lengthen approval timelines and delay market entry.
Collaborations, such as the March 2024 partnership between Roche Diagnostics and Pfizer, are focused on co-developing companion diagnostics for oncology drug trials. These alliances accelerate the validation process and help pharmaceutical companies use biomarkers for patient stratification in clinical trials.
Hospitals and clinics represent the largest end-use segment. They serve as the primary diagnostic and treatment checkpoints for patients, where clinicians increasingly rely on blood-based biomarkers to identify therapeutic windows and make rapid, data-driven clinical decisions.
In July 2024, the U.S. FDA granted approval to Guardant Health’s Shield™ blood test for colorectal cancer screening. This landmark clearance is a major step forward for the clinical acceptance of liquid biopsies in routine population-based screening.
AI-driven analytics and cloud-based bioinformatics are being integrated with sequencing platforms to improve the interpretation of complex genetic data. This integration enhances the precision of clinical decision-making and allows for the development of more accurate, high-throughput biomarker panels.
